Business Wire

MA-NETSCOUT-SYSTEMS

2.11.2021 12:57:11 CET | Business Wire | Press release

Share
NETSCOUT Announces Availability of Omnis Cyber Intelligence

NETSCOUT SYSTEMS, INC ., (NASDAQ: NTCT), a leading provider of cybersecurity, service assurance, and business analytics solutions, today announced the availability of Omnis® Cyber Intelligence (OCI), the industry's fastest and most scalable network security software solution, built on the foundation of the industry's most prominent network monitoring and packet recording and analysis technology. It uniquely detects and investigates suspicious activities in real-time and retrospectively, identifies threats early in the attack life cycle to prevent infections from spreading, stops future attacks, and identifies compromised assets.

With cyberattacks increasing and breaches making front-page news, IT security teams find that their existing tools are no match for this growing threat, and both their expenses and their cyber risk are growing out of control. This the case because the typical data sets feeding these tools are reactive, not granular, and do not extend to the earliest indications of a potential attack.

NETSCOUT's approach to turn the situation around is to leverage its market-leading visibility technology to increase the range and depth of security intelligence and make it accessible to security teams in real-time. The solution consists of an analytics stack and cyber security software sensors called Omnis CyberStreams.

NETSCOUT's Omnis Cyber Intelligence arms security teams with proactive, actionable intelligence helping them to:

  • Perform continuous scanning and analysis for reconnaissance to detect attacks earlier, minimizing exposure and, in many cases, thwarting the threat.
  • Rapidly access high-resolution historical evidence far back in time to understand how an attack started to prevent similar breaches and stop ongoing malicious activity.
  • Monitor exposed attack surfaces within their infrastructure to optimize the effectiveness of the defenses deployed.
  • Evaluate the extent of penetration and impacted assets when attacks occur to prevent malware from spreading.
  • Deploy on-premises, in virtualized data centers, and the public cloud, supporting an organization's evolving deployment preferences without impacting security governance and workflows.
  • Integrate with their security ecosystem through APIs and partnerships with leading vendors such as Splunk, Palo Alto Networks, and AWS.

As a result, the effectiveness of customers' existing security tools and the productivity of analysts improve, and they can get ahead of the vicious cycle of both rising costs and rising cyber risk.

"NETSCOUT's unique ASI technology allows companies to truly unlock the actionable intelligence embedded in network transactions and packets," said Christopher Kissel, research director, security and trust products, IDC. "Where others have failed, NETSCOUT has made the use of packet data fast and affordable with their patented metadata extraction, intelligent reduction, and indexing. Omnis Cyber Intelligence provides security analysts with the information they need to quickly and accurately assess the scope and scale of an incident and reduce the associated risk and negative impact."

"Enterprises have invested heavily in cybersecurity solutions, but they are largely ineffective because they lack the actionable visibility needed to spot attacks before they have broad impact," stated Sanjay Munshi, vice president, product management, NETSCOUT. "As attack surfaces expand, the Omnis Cyber Intelligence solution extends throughout the infrastructure, integrates into existing ecosystems, and becomes part of the growing movement towards XDR, using meaningful metadata, or smart data, and powerful cyber analytics to quickly get to the root cause of the cybersecurity issue and mitigate risk."

For more information about the Omnis Cyber Intelligence solution, please visit https://www.netscout.com/solutions/omnis-security .

About NETSCOUT

NETSCOUT SYSTEMS, INC. (NASDAQ: NTCT) helps assure digital business services against security, availability, and performance disruptions. Our market and technology leadership stems from combining our patented smart data technology with smart analytics. We provide real-time, pervasive visibility and insights customers need to accelerate and secure their digital transformation. Omnis® Cyber Intelligence delivers the fastest and most scalable network security solution available on the market. NETSCOUT nGenius® service assurance solutions provide real-time, contextual analysis of service, network, and application performance. And Arbor® Smart DDoS Protection by NETSCOUT products help protect against attacks that threaten availability and advanced threats that infiltrate networks to steal critical business assets. To learn more about improving service, network, and application performance in physical or virtual data centers or in the cloud, and how NETSCOUT's security and performance solutions can help you move forward with confidence, visit www.netscout.com or follow @NETSCOUT on Twitter, Facebook, or LinkedIn.

©2021 NETSCOUT SYSTEMS, INC. All rights reserved. NETSCOUT, the NETSCOUT logo, Guardians of the Connected World, Adaptive Service Intelligence, Arbor, ATLAS, Cyber Threat Horizon, InfiniStream, nGenius, nGeniusONE, and Omnis are registered trademarks or trademarks of NETSCOUT SYSTEMS, INC., and/or its subsidiaries and/or affiliates in the USA and/or other countries. Third-party trademarks mentioned are the property of their respective owners.

Social Media:

https://www.facebook.com/NETSCOUTinc

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release

MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release

Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye